{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:43:35Z","timestamp":1785192215406,"version":"3.55.0"},"reference-count":73,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA055695"],"award-info":[{"award-number":["K23DA055695"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R34DA061732"],"award-info":[{"award-number":["R34DA061732"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM125507"],"award-info":[{"award-number":["P20GM125507"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) remains a leading cause of infectious disease-related morbidity in the USA, disproportionately affecting people who inject drugs and people who are incarcerated. Despite the availability of highly effective, highly tolerated direct-acting antivirals, treatment uptake in jails remains limited due to short stays, unpredictable release dates and system-level barriers. The original MINMON trial demonstrated that a low barrier \u2018minimal monitoring\u201d\u2019 model can achieve high cure rates in community settings. This study, MINMON-J, aims to adapt and evaluate a modified version of the MINMON model for use in a jail setting, addressing the urgent need for scalable, low-barrier treatment approaches among justice-involved individuals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>MINMON-J is a single-arm, hybrid effectiveness-implementation pilot study protocol planned to recruit at the Rhode Island Department of Corrections. 40 people who are incarcerated with positive HCV RNA, who are treatment-na\u00efve, without cirrhosis and awaiting trial, will receive 12 weeks of sofosbuvir\/velpatasvir with no required lab monitoring during treatment. If released before treatment completion, participants will receive their remaining medication at discharge. Community health workers will provide post-release support. Mixed-methods evaluation will be guided by the Reach, Effectiveness, Adoption, Implementation and Maintenance\/Practical, Robust Implementation and Sustainability Model framework. Primary outcomes include feasibility, acceptability and adherence. Data will be collected through administrative records, surveys (Acceptability of Intervention Measure, Feasibility of Intervention Measure, Brief Adherence Rating Scale) and qualitative interviews with participants and other relevant parties. This study was reviewed and approved by the Brown University Health Institutional Review Board (2240400) and the Rhode Island Department of Corrections Medical Research Advisory Group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study was reviewed and approved by the Brown University Health Institutional Review Board (2240400) and the Rhode Island Department of Corrections (RIDOC) Medical Research Advisory Group. All participants will provide written informed consent prior to enrolment. People who are incarcerated will be assured that participation is voluntary, will not impact their clinical care and that they may withdraw at any time without penalty. Study procedures follow ethical principles outlined in the Declaration of Helsinki and comply with federal regulations regarding research involving vulnerable populations.<\/jats:p>\n                  <jats:p>Dissemination of findings will include peer-reviewed publications and presentations at national conferences focused on infectious diseases, implementation science and\/or correctional health. Lay summaries will be shared with RIDOC leadership and community partners. De-identified data and associated metadata may be archived in a publicly accessible repository in accordance with National Institutes of Health data sharing policies, contingent on final institutional review board approval and participant protections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06953479\">NCT06953479<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-104839","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T09:16:34Z","timestamp":1759223794000},"page":"e104839","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["MINMON-J: a hybrid implementation pilot study evaluating a low-barrier hepatitis C treatment model in a jail setting"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06953479","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Justin","family":"Berk","sequence":"first","affiliation":[{"name":"Brown University Warren Alpert Medical School, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Human Behavior, Brown University Warren Alpert Medical School, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Murphy","sequence":"additional","affiliation":[{"name":"Brown University Warren Alpert Medical School, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiah D","family":"Rich","sequence":"additional","affiliation":[{"name":"Brown University Warren Alpert Medical School, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Elizabeth","family":"Frank","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Human Behavior, Brown University Warren Alpert Medical School, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025093002152216000_15.9.e104839.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26218"},{"key":"2025093002152216000_15.9.e104839.2","doi-asserted-by":"crossref","first-page":"103283","DOI":"10.1016\/j.drugpo.2021.103283","article-title":"Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions","volume":"96","author":"Taweh","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2025093002152216000_15.9.e104839.3","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2025093002152216000_15.9.e104839.4","doi-asserted-by":"publisher","DOI":"10.1177\/003335491412900213"},{"key":"2025093002152216000_15.9.e104839.5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26387"},{"key":"2025093002152216000_15.9.e104839.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1311941"},{"key":"2025093002152216000_15.9.e104839.7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jama.2023.11757","article-title":"US Hepatitis C Elimination Plan","volume":"330","author":"Berk","year":"2023","journal-title":"JAMA"},{"key":"2025093002152216000_15.9.e104839.8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2024.20602","article-title":"The Carceral-Community Cascade and HCV Elimination","volume":"333","author":"Akiyama","year":"2025","journal-title":"JAMA"},{"key":"2025093002152216000_15.9.e104839.9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41575-020-00392-3","article-title":"Hepatitis C virus elimination: laying the foundation for achieving 2030 targets","volume":"18","author":"Dore","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025093002152216000_15.9.e104839.10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw111"},{"key":"2025093002152216000_15.9.e104839.11","unstructured":"U.S. Department of Health & Human Services . Viral hepatitis national strategic plan for the united states: a roadmpa to elimination 2021 - 2025 toolkit. 2021. Available: https:\/\/www.hhs.gov\/hepatitis\/viral-hepatitis-national-strategic-plan\/background-and-history\/viral-hepatitis-community-action\/toolkit\/messages.html [Accessed 20 Sep 2022]."},{"key":"2025093002152216000_15.9.e104839.12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1377\/hlthaff.2018.05232","article-title":"A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C","volume":"38","author":"Powell","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"2025093002152216000_15.9.e104839.13","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.304132"},{"key":"2025093002152216000_15.9.e104839.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810477"},{"key":"2025093002152216000_15.9.e104839.15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2023.3692","article-title":"A National Hepatitis C Elimination Program in the United States: A Historic Opportunity","volume":"329","author":"Fleurence","year":"2023","journal-title":"JAMA"},{"key":"2025093002152216000_15.9.e104839.16","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575"},{"key":"2025093002152216000_15.9.e104839.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"2025093002152216000_15.9.e104839.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"2025093002152216000_15.9.e104839.19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00077-7","article-title":"Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study","volume":"6","author":"Hajarizadeh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025093002152216000_15.9.e104839.20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025093002152216000_15.9.e104839.21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","article-title":"Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial","volume":"7","author":"Litwin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025093002152216000_15.9.e104839.22","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab488","article-title":"Adherence to Hepatitis C Therapy in a Shelter-Based Education and Treatment Model Among Persons Experiencing Homelessness","volume":"8","author":"Powell","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025093002152216000_15.9.e104839.23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx142","article-title":"Feasibility of Treating Hepatitis C in a Transient Jail Population","volume":"4","author":"MacDonald","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2025093002152216000_15.9.e104839.24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025093002152216000_15.9.e104839.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31060"},{"key":"2025093002152216000_15.9.e104839.26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ396"},{"key":"2025093002152216000_15.9.e104839.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2010.12.041"},{"key":"2025093002152216000_15.9.e104839.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.029"},{"key":"2025093002152216000_15.9.e104839.29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26431"},{"key":"2025093002152216000_15.9.e104839.30","doi-asserted-by":"publisher","DOI":"10.1177\/003335490512000208"},{"key":"2025093002152216000_15.9.e104839.31","doi-asserted-by":"publisher","DOI":"10.1007\/S10461-021-03296-8\/TABLES\/2"},{"key":"2025093002152216000_15.9.e104839.32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy210"},{"key":"2025093002152216000_15.9.e104839.33","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/infdis\/jiad227","article-title":"Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States","volume":"228","author":"Spaulding","year":"2023","journal-title":"J Infect Dis"},{"key":"2025093002152216000_15.9.e104839.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4344-1","article-title":"Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial","volume":"19","author":"Akiyama","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025093002152216000_15.9.e104839.35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","article-title":"Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial","volume":"182","author":"Eckhardt","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025093002152216000_15.9.e104839.36","doi-asserted-by":"crossref","DOI":"10.1186\/s43058-024-00573-0","article-title":"Locked in and left out: the \u201cprison penalty\u201d for implementation of evidence-based interventions","volume":"5","author":"Berk","year":"2024","journal-title":"Implement Sci Commun"},{"key":"2025093002152216000_15.9.e104839.37","unstructured":"Berk J , Akiyama MJ , Schachman N , et al . Hepatitis C Treatment in a Jail Setting: A Retrospective Analysis of Low-Barrier Initiation of Direct Acting Antivirals. International Journal of Drug Policy 2025."},{"key":"2025093002152216000_15.9.e104839.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100567","article-title":"The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017","volume":"27","author":"Chan","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025093002152216000_15.9.e104839.39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures","volume":"3","author":"Evans","year":"2010","journal-title":"J Exp Stroke Transl Med"},{"key":"2025093002152216000_15.9.e104839.40","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/hep.32053","article-title":"A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study","volume":"74","author":"Sulkowski","year":"2021","journal-title":"Hepatology"},{"key":"2025093002152216000_15.9.e104839.41","doi-asserted-by":"crossref","DOI":"10.1186\/s43058-024-00646-0","article-title":"Expanding methods to address RE-AIM metrics in hybrid effectiveness-implementation studies","volume":"5","author":"Harden","year":"2024","journal-title":"Implement Sci Commun"},{"key":"2025093002152216000_15.9.e104839.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1553-7250(08)34030-6"},{"key":"2025093002152216000_15.9.e104839.43","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780141709"},{"key":"2025093002152216000_15.9.e104839.44","doi-asserted-by":"publisher","DOI":"10.1097\/mlr.0000000000001664"},{"key":"2025093002152216000_15.9.e104839.45","doi-asserted-by":"crossref","unstructured":"Bhattacharya D , Aronsohn A , Price J , et al . Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases\u2013 Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2023. doi:10.1093\/cid\/ciad319","DOI":"10.1093\/cid\/ciad319"},{"key":"2025093002152216000_15.9.e104839.46","doi-asserted-by":"publisher","DOI":"10.1177\/003335491012500205"},{"key":"2025093002152216000_15.9.e104839.47","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.300894"},{"key":"2025093002152216000_15.9.e104839.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028097","article-title":"Propensity-matched study of enhanced primary care on contact with the criminal justice system among individuals recently released from prison to New Haven","volume":"9","author":"Wang","year":"2019","journal-title":"BMJ Open"},{"key":"2025093002152216000_15.9.e104839.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1815382"},{"key":"2025093002152216000_15.9.e104839.50","doi-asserted-by":"crossref","first-page":"107514","DOI":"10.1016\/j.drugalcdep.2019.06.016","article-title":"The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting","volume":"205","author":"Brinkley-Rubinstein","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2025093002152216000_15.9.e104839.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.12.470"},{"key":"2025093002152216000_15.9.e104839.52","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-017-0635-3","article-title":"Psychometric assessment of three newly developed implementation outcome measures","volume":"12","author":"Weiner","year":"2017","journal-title":"Implement Sci"},{"key":"2025093002152216000_15.9.e104839.53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.childyouth.2013.10.006","article-title":"The Cost of Implementing New Strategies (COINS): A Method for Mapping Implementation Resources Using the Stages of Implementation Completion","volume":"39","author":"Saldana","year":"2014","journal-title":"Child Youth Serv Rev"},{"key":"2025093002152216000_15.9.e104839.54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/cid\/ciab913","article-title":"Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments","volume":"75","author":"Weld","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025093002152216000_15.9.e104839.55","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X05279903"},{"key":"2025093002152216000_15.9.e104839.56","doi-asserted-by":"crossref","first-page":"112629","DOI":"10.1016\/j.psychres.2019.112629","article-title":"Reprint of: Qualitative methods in implementation research: An introduction","volume":"283","author":"Hamilton","year":"2020","journal-title":"Psychiatry Res"},{"key":"2025093002152216000_15.9.e104839.57","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-017-0574-8"},{"key":"2025093002152216000_15.9.e104839.58","doi-asserted-by":"publisher","DOI":"10.1177\/10778004231183948"},{"key":"2025093002152216000_15.9.e104839.59","doi-asserted-by":"publisher","DOI":"10.1080\/2159676x.2019.1704846"},{"key":"2025093002152216000_15.9.e104839.60","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215588241"},{"key":"2025093002152216000_15.9.e104839.61","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s12671-024-02366-x","article-title":"Mindfulness-Based Stress Reduction Health Insurance Coverage: If, How, and When? An Integrated Knowledge Translation (iKT) Delphi Key Informant Analysis","volume":"15","author":"Frank","year":"2024","journal-title":"Mindfulness (N Y)"},{"key":"2025093002152216000_15.9.e104839.62","doi-asserted-by":"crossref","unstructured":"Rosen RK , Gainey M , Nasrin S , et al . Use of Framework Matrix and Thematic Coding Methods in Qualitative Analysis for mHealth: NIRUDAK Study Data. Int J Qual Methods 2023;22. doi:10.1177\/16094069231184123","DOI":"10.1177\/16094069231184123"},{"key":"2025093002152216000_15.9.e104839.63","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-018-0842-6"},{"key":"2025093002152216000_15.9.e104839.64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/jvh.13454","article-title":"High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting","volume":"28","author":"Fabbiani","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025093002152216000_15.9.e104839.65","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jvh.13600","article-title":"Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in Phase 2 and 3 clinical trials","volume":"28","author":"Gane","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025093002152216000_15.9.e104839.66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11524-015-9953-4","article-title":"A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System","volume":"92","author":"Nguyen","year":"2015","journal-title":"J Urban Health"},{"key":"2025093002152216000_15.9.e104839.67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1078345818805770","article-title":"Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism","volume":"25","author":"Spaulding","year":"2019","journal-title":"J Correct Health Care"},{"key":"2025093002152216000_15.9.e104839.68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2105\/AJPH.2018.304362","article-title":"Drug Purchasing Strategies to Treat People With Hepatitis C in the Criminal Justice System","volume":"108","author":"Akiyama","year":"2018","journal-title":"Am J Public Health"},{"key":"2025093002152216000_15.9.e104839.69","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJMp2119571","article-title":"Strengthening the Medicaid Reentry Act \u2014 Supporting the Health of People Who Are Incarcerated","volume":"386","author":"Khatri","year":"2022","journal-title":"N Engl J Med"},{"key":"2025093002152216000_15.9.e104839.70","unstructured":"Center for Medicaid Services . HHS approves california\u2019s medicaid and children\u2019s health insurance plan (chip) demonstration authority to support care for justice-involved people. 2023."},{"key":"2025093002152216000_15.9.e104839.71","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1353\/hpu.2023.a903067","article-title":"Incarceration, Inequality, and Hepatitis C Treatment: The Story of Two Southern States","volume":"34","author":"Wennerstrom","year":"2023","journal-title":"J Health Care Poor Underserved"},{"key":"2025093002152216000_15.9.e104839.72","doi-asserted-by":"crossref","unstructured":"Bialek T , Akiyama M . Policies for Expanding Hepatitis C Testing and Treatment in United States Prisons and Jails. MJLR 2024;1. doi:10.36646\/mjlr.57.1.policies","DOI":"10.36646\/mjlr.57.1.policies"},{"key":"2025093002152216000_15.9.e104839.73","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa377","article-title":"Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents","volume":"7","author":"Norton","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-104839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T09:16:43Z","timestamp":1759223803000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-104839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":73,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2025-104839"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-104839","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}